Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.
Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the induction by active vaccination of antibodies that can potently neutralize a broad range of circulating virus strains is a goal not yet achieved, despite more than 2 decades of research. Here we review progr...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1826297682332745728 |
|---|---|
| author | Kong, L Sattentau, Q |
| author_facet | Kong, L Sattentau, Q |
| author_sort | Kong, L |
| collection | OXFORD |
| description | Neutralizing antibodies can protect from infection by immunodeficiency viruses. However, the induction by active vaccination of antibodies that can potently neutralize a broad range of circulating virus strains is a goal not yet achieved, despite more than 2 decades of research. Here we review progress made in the field, from early empirical studies to today's rational structure-based vaccine antigen design. We discuss the existence of broadly neutralizing antibodies, their implications for epitope discovery and recent progress made in antigen design. Finally, we consider the relationship between antigenicity and immunogenicity for B cell recognition and antibody production, a major hurdle for rational vaccine design to overcome. |
| first_indexed | 2024-03-07T04:35:23Z |
| format | Journal article |
| id | oxford-uuid:cfbe4b09-217b-4a05-89ac-68414f3e0320 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:35:23Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:cfbe4b09-217b-4a05-89ac-68414f3e03202022-03-27T07:44:52ZAntigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cfbe4b09-217b-4a05-89ac-68414f3e0320EnglishSymplectic Elements at Oxford2012Kong, LSattentau, QNeutralizing antibodies can protect from infection by immunodeficiency viruses. However, the induction by active vaccination of antibodies that can potently neutralize a broad range of circulating virus strains is a goal not yet achieved, despite more than 2 decades of research. Here we review progress made in the field, from early empirical studies to today's rational structure-based vaccine antigen design. We discuss the existence of broadly neutralizing antibodies, their implications for epitope discovery and recent progress made in antigen design. Finally, we consider the relationship between antigenicity and immunogenicity for B cell recognition and antibody production, a major hurdle for rational vaccine design to overcome. |
| spellingShingle | Kong, L Sattentau, Q Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. |
| title | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. |
| title_full | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. |
| title_fullStr | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. |
| title_full_unstemmed | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. |
| title_short | Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. |
| title_sort | antigenicity and immunogenicity in hiv 1 antibody based vaccine design |
| work_keys_str_mv | AT kongl antigenicityandimmunogenicityinhiv1antibodybasedvaccinedesign AT sattentauq antigenicityandimmunogenicityinhiv1antibodybasedvaccinedesign |